Tumoral pseudoangiomatous stromal hyperplasia (PASH) of the male breast: A systematic analysis.

<b><br>Aim:</b> The study was conducted to systematically analyze the recent peer-reviewed literature related to tumoral pseudoangiomatous stromal hyperplasia (PASH) in males.</br> <b><br>Materials and methods:</b> Articles published in peer-reviewed journals of repute from 2012 to 2023 were evaluated for eight variables: 1) the age of the patient, 2) clinical presentation, 3) laterality (unilateral or bilateral), 4) associated breast disorder, 5) the presence of systemic co-morbidity, 6) imaging modalities aiding diagnosis, 7) treatment, and 8) recurrence.</br> <b><br>Results:</b> There were 10 patients ranging in age from 1 year to 67 years (mean: 34.5 years). In 8 cases (80%), there were breast lumps; in 2 cases (20%), there were axillary lumps at presentation. Pain was not a prominent symptom. Six patients (60%) had another breast disorder at presentation and 3 (30%) had significant systemic co-morbidities, including diabetes and renal insufficiency. The greatest dimension of the lumps ranged from 2 cm to 12 cm, with 80% of the lumps being below 5 cm in size. Imaging modalities utilized in evaluation included breast ultrasound (USG), mammograms, computerized tomography (CT), and magnetic resonance imaging (MRI). All the cases were treated surgically, and the final diagnosis was made only after the analysis of the surgical specimen. Recurrence was recorded in 2 (20%) cases.</br> <b><br>Conclusions:</b> Tumoral PASH is a benign myofibroblastic proliferation disorder rarely reported in males. This condition should be considered a differential diagnosis of breast or axillary lumps, and an evaluation should be initiated accordingly. The recommended course of treatment is adequate surgical excision with regular clinical and radiological follow-up.</br>.

Factors predicting caregivers' readiness for vaccination of 5-11 years old children against SARS-CoV-2 - Saudi Arabia, 2022.

INTRODUCTION: A significant proportion of parents are still reluctant to have their children vaccinated against COVID-19. This study aimed to determine what factors influence parents' decision to get COVID-19 vaccine for the children of age group 5-11 years. METHODOLOGY: A cross-sectional study was conducted in the region Qassim of Saudi Arabia, by using a self-administered, pre-tested questionnaire to assess the predicting factors of caregivers' readiness to get their children vaccinated against COVID-19. RESULTS: Two-thirds of the caregivers surveyed were unwilling to get their children vaccinated against COVID-19. The factors that influence the parents' decision to get their young children (5-11 years old) vaccinated against COVID-19 were: having secondary school education (p = 0.019), family members infected with SARS-CoV-2 (p = 0.016), caregivers completed the three doses of vaccination (p = 0.003) and those who received additional flu vaccine (p = 0.014), and not experiencing the side effects of COVID-19 vaccine (p = 0.0001). Additionally, no history of COVID-19 vaccine adverse events in older 12-18 year old children (p = 0.011) and no chronic diseases in the 5-11 year old children (p = 0.001) were predictors. CONCLUSIONS: Caregivers' preferences about the children's vaccination were influenced by multiple factors, including educational level, having family members infected with SARS-CoV-2, caregivers completing three doses of COVID-19 vaccine, receiving additional flu vaccine with no or mild adverse events, and history of chronic diseases in the child. Understanding these factors can help determine the likelihood of the caregivers getting their child vaccinated.